SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today ...

Vertical farms, woke AI, and 23andMe made our annual list of failed tech. Hundreds of LLM-powered AI agents spontaneously ...

Genetic testing company 23andMe had a particularly rough year. The company went public via a SPAC in 2021, valuing the ...

23andMe, born from the techno-optimism of the Human Genome Project, revolutionized direct-to-consumer genetic testing. But with its valuation now in freefall, mounting layoffs and its board ...

23andMe, born from the techno-optimism of the Human Genome Project, revolutionized direct-to-consumer genetic testing. But with its valuation now in freefall, mounting layoffs and its board ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

23andMe, a major company providing direct-to-consumer genetic testing, has been struggling financially since late 2023. In September 2024, the company's stock hit a rock-bottom of US$0.30, down 96 ...

Aimed at broadening the range of artificial intelligence applications via agentic capabilities and multimodal processing, Alphabet's (GOOG, Financials) Google DeepMind has revealed the release of ...

23andMe, a major company providing direct-to-consumer genetic testing, has been struggling financially since late 2023. In September 2024, the company’s stock hit a rock-bottom of US$0.30, down 96 per ...

Just over a year ago, 23andMe’s co-founder and CEO Anne Wojcicki was assuring the life sciences industry that the company was a “full-fledged biotech” committed to drug R&D. “We have real ...